Compare TSAT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | LCTX |
|---|---|---|
| Founded | 1969 | 1990 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 407.7M |
| IPO Year | 1996 | N/A |
| Metric | TSAT | LCTX |
|---|---|---|
| Price | $29.16 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 113.0K | ★ 1.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,440,552.00 | $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $14.31 | $0.37 |
| 52 Week High | $36.85 | $2.09 |
| Indicator | TSAT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 46.04 |
| Support Level | $28.65 | $1.58 |
| Resistance Level | $31.00 | $1.77 |
| Average True Range (ATR) | 2.16 | 0.08 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 21.63 | 32.65 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.